Skip to main content
    L

    Liminatus Pharma, Inc. Class A Common Stock (LIMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.25
    +0.00 (+0.00%)

    Market Cap: $4.37M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 14
    		$-0.03N/AN/ABeat-112.3%
    Mar 26
    Reported May 15
    		$-1.56N/AN/ABeat-1200.6%
    Dec 25
    Reported Mar 31
    		$-15.09N/AN/ABeat-145.9%
    Sep 25
    Reported Oct 3
    		$-0.07$0.00N/AMiss+98.4%
    Jun 25
    Reported Jun 30
    		$0.24N/AN/ABeat+106.5%
    Mar 25
    Reported Apr 16
    		$-0.12N/AN/ABeat+98.0%
    Dec 24
    Reported Dec 31
    		$-6.14N/AN/ABeat-84.3%
    Sep 24
    Reported Sep 30
    		$-4.48N/AN/ABeat-124.9%
    Jun 24
    Reported Jun 30
    		$-3.72N/AN/ABeat-365.5%
    Mar 24
    Reported Mar 31
    		$-5.90N/AN/ABeat-7462.1%
    Dec 23
    Reported Dec 31
    		$-3.33N/AN/ABeat-5102.8%
    Sep 23
    Reported Sep 30
    		$-1.99N/AN/ABeat-2590.9%
    Jun 23
    Reported Jun 30
    		$1.40N/AN/ABeat+1173.9%
    Mar 23
    Reported Apr 18
    		$-0.08N/AN/ABeat-680.0%
    Dec 22
    Reported Dec 31
    		$-0.06N/AN/ABeat+83.5%
    Sep 22
    Reported Nov 21
    		$0.08N/AN/ABeat-60.0%
    Jun 22
    Reported Aug 19
    		$0.11N/AN/ABeat+283.3%
    Mar 22
    Reported Apr 18
    		$-0.01N/AN/ABeat-
    Dec 21
    Reported Dec 31
    		$-0.39N/AN/ABeat-
    Sep 21
    Reported Nov 22
    		$0.20N/AN/ABeat-
    Jun 21
    Reported Jul 22
    		$-0.06N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE0.00%ROIC-247.19%
    Financial Health
    Debt/Equity4.80xInterest Coverage-72.16x
    Current Ratio1.12xQuick Ratio1.12x
    Trading Statistics
    Beta0.75Avg Volume23.27K
    52-Week High$141.5052-Week Low$3.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.63
    SMA 20$3.78
    SMA 50$4.32
    SMA 200$12.93
    EMA 10$3.55
    EMA 20$3.71
    EMA 50$4.35
    EMA 200$37.72

    MACD

    Line: -0.22Signal: -0.20Hist: -0.03

    ADX

    ADX: 26.9+DI: 10.5-DI: 11.0

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down100.0
    PSAR$4.48

    Bollinger Bands

    Upper Band$4.38
    Lower Band$3.17
    %B Position3205%(Upper)
    Band Width0.06

    RSI (14-Day)

    Neutral
    36.2

    Momentum Oscillators

    Stoch %K1.4
    Stoch %D4.4
    Williams %R-96.8
    ROC (10d)-13.3%
    Momentum-0.50
    CCI (20d)-161.4
    MFI (14d)28.9

    Volatility Measures

    ATR (14d)$0.60(18.5%)
    StdDev (20d)0.30
    Hist Vol81.0%(High)

    Volume Flow

    VWAP$3.27
    OBV2.4B
    AD Line1130.1B
    CMF (20d)-0.084

    Volume Metrics

    Avg Vol (20d)24.4K
    Vol Ratio0.6x
    VWMA (20d)$3.82

    Pivot Points

    R3$3.75
    R2$3.65
    R1$3.45
    Pivot Point$3.35
    S1$3.15
    S2$3.05
    S3$2.85

    Advanced Oscillators

    TSI-17.75
    Ultimate Osc35.1
    KST-100.68

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0N/A
    Cost of Revenue$0$0$-255$0$0$0N/A$0$0$0N/AN/A
    Gross Profit$0$0$255$0$0$0N/A$0$0$0N/AN/A
    Operating Expenses$1.38M$1.10M$1.15M$701,170$1.12M$264,220$1.88M$543,147$909,218$247$642,699$676,321
    R&D$600,000$400,000$0$0$0$0$0$357,066$714,134$0$715,000$0
    SG&A$778,908$700,898$0$701,170$1.12M$264,220$0$186,081$195,084$0$47,000$0
    Operating Income$-1,378,908$-1,100,898$-1,148,176$-701,170$-1,118,211$-264,220$-1,877,341$-543,147$-909,218$-247$-642,699$-676,321
    Interest Income$8,223$0$0$0$24,383$52,206$0$34,481$25,231$0$8,000$0
    Interest Expense$18,844$18,638$7.35M$19,052$62,288$115,512$106,142$92,706$77,220$0$17,000$0
    Income Before Tax$-1,407,259$-1,123,714$-8,496,198$-1,823,351$113,287$-327,526$-1,983,483$-601,372$-961,207$-247$-472,995$-300,290
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$13,600$23,601
    Net Income$-1,407,259$-1,123,714$-8,496,198$-1,823,351$113,287$-327,526$-1,983,483$-601,372$-961,207$-247$-486,595$-323,891
    EBITDA$-1,396,170$-1,104,558$-1,147,633$-1,803,757$151,935$-264,220$-1,877,341$-543,147$-909,218$-247$-369,906$-300,290
    EBIT$-1,396,638$-1,105,076$-1,148,176$-1,804,299$151,192$-264,220$-1,877,341$-543,147$-909,218$-247N/AN/A
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LIMN

    News

    Liminatus Pharma Regains Nasdaq Compliance After Reverse Split

    Liminatus Pharma regained compliance with Nasdaq's minimum bid price rule after implementing a 1-for-50 reverse stock split. The company was initially notified in January 2026 for falling below the $1.00 minimum and was...

    The Globe and Mail•9/30/26•Bullish

    Liminatus Pharma Regains Nasdaq Compliance

    Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule after its stock fell below $1.00 for 30 consecutive business days. The company previously executed a 1-for-50 reverse stock split...

    Intellectia AI•9/30/26•Bullish

    Liminatus Pharma Regains Compliance With Nasdaq Minimum Bid Price Rule

    Liminatus Pharma has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq confirming its compliance, effective September 27...

    Moomoo•9/29/26•Neutral

    Form 8K Liminatus Pharma Inc Class A For: 29 September By Investing.com

    Investing.com reported on September 29, 2026, about the filing of Form 8K by Liminatus Pharma Inc. Class A. The article title states the filing is "For: 29 September."

    Investing.com Nigeria•9/29/26•Bearish

    Form 8K Liminatus Pharma Inc Class A For: 29 September By Investing.com

    This article announces the filing of a Form 8K by Liminatus Pharma Inc Class A on September 29, 2026. The content is a brief financial news item from Investing.com, indicating a -5.62% change for LIMN.

    Investing.com UK•9/29/26•Neutral

    LIMN Valuation and Fair Value

    P/E
    -0.0x
    P/B
    10.5x
    See GNG's fair value

    LIMN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -247.2%
    ROE
    0.0%

    LIMN Competitors

    CompanyTicker
    Dermata Therapeutics IncDRMA
    Azitra IncAZTR
    NuCana PLCNCNA
    Jupiter Neurosciences, Inc. Common StockJUNS
    Enlivex Therapeutics LtdENLV
    cbdMD IncYCBD
    Vivos Therapeutics IncVVOS
    PharmaCyte Biotech IncPMCB

    Sector: Healthcare

    LIMN Bull Case vs Bear Case

    Bear case

    • LIMN has a debt-to-equity ratio of 4.8x.

    Frequently Asked Questions About LIMN

    Does LIMN pay dividends?

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay a regular dividend.

    What is LIMN's market cap?

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of $4.37M with a current stock price of $3.25.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In